Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955164 | 1.00 | GLS (0.38) | GLSADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL8629991 | 0.76 | — | — | |
| SCHEMBL6672819 | 0.73 | PIM1 (0.37) | PIM1EDNRBEDNRA | |
| SCHEMBL916737 | 0.71 | ALDH1A1 (0.53) | GLSADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL28850201 | 0.71 | ALDH1A1 (0.53) | GLSADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL30991817 | 0.70 | AR (0.36) | GLSADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL2955165 | 0.70 | AR (0.36) | GLSADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL15107233 | 0.69 | GLS (0.46) | GLSADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL15129174 | 0.69 | GLS (0.46) | GLSADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL15129443 | 0.69 | GLS (0.46) | GLSADORA3ARHSD11B1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5688906-A | Highly efficient nonlinear optical polyimides | ENICHEM S.P.A. (IT) | 1997-11-18 | — | — | US | claimed |
| US-5679763-A | Polyquinoline-based nonlinear optical materials | ENICHEM S.P.A. (IT) | 1997-10-21 | — | — | US | claimed |
| EP-0791849-A1 | Non-linear optical compounds | ENICHEM S.p.A. (IT) | 1997-08-27 | — | — | EP | claimed |
| EP-0729056-A1 | Polyquinoline-based nonlinear optical materials | ENICHEM S.p.A. (IT) | 1996-08-28 | — | — | EP | claimed |
| US-5514799-A | 1,1-vinyl substituted nonlinear optical materials | ENICHEM S.P.A. (IT) | 1996-05-07 | — | — | US | claimed |
| EP-0647874-A1 | Highly efficient nonlinear optical polyimides | ENICHEM S.p.A. (IT) | 1995-04-12 | — | — | EP | claimed |
| EP-0637774-A1 | 1,1-Vinyl substituted nonlinear optical materials | ENICHEM S.p.A. (IT) | 1995-02-08 | — | — | EP | claimed |
| JP-11002847-A | — | — | None | — | — | JP | disclosed |
| US-7759356-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7754730-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1673354-B1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-26 | — | — | US | disclosed |
| US-7468373-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-0791849-A1 | Non-linear optical compounds | ENICHEM S.p.A. (IT) | 1997-08-27 | — | — | EP | disclosed |
| EP-0729056-A1 | Polyquinoline-based nonlinear optical materials | ENICHEM S.p.A. (IT) | 1996-08-28 | — | — | EP | disclosed |
| EP-0727692-A2 | Process for intramolecularly condensing a non-linear optical polyamic acid composition | ENICHEM S.p.A. (IT) | 1996-08-21 | — | — | EP | disclosed |
| US-5514799-A | 1,1-vinyl substituted nonlinear optical materials | ENICHEM S.P.A. (IT) | 1996-05-07 | — | — | US | disclosed |
| EP-0647874-A1 | Highly efficient nonlinear optical polyimides | ENICHEM S.p.A. (IT) | 1995-04-12 | — | — | EP | disclosed |
| EP-0602654-A1 | Efficient electron-donating groups for nonlinear optical applictions | ENICHEM S.p.A. (IT) | 1994-06-22 | — | — | EP | disclosed |
| EP-0585999-A1 | Functional heteroaromatics for NLO applications | ENICHEM S.p.A. (IT) | 1994-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | GLS 1732/4885ADORA3 3/4885AR 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.